Immix Biopharma Investor Presentation Deck
iMX-110 Pancreatic Preclinical KPC Mouse Model:
(iMX-110 + PD-1) Outperforms (Gem + Pac + PD-1 + CD-40)
Median Survival Comparison |
Pdx1-Cre (KPC mice) Panc
Model
mOS (Days)
IMMIX IMX-110 + PD-1
Perelman
SCHOOL OF MEDIMINE
Usestry of PENYANA
CD40/G/NP +
PD-1
63
1 450%
42
IMMIX Immix Biopharma Unpublished Data
KPC Mice Survival (90 Days)
120
Dosing Schedule
IMX-110
aPD-1
80
40
0
120
80
40
Dosing Schedule
Gemcitabine (G)
nab-Paclitaxel (np)
aPD-1
aCD40
0
0
Pancreatic Pdx1-Cre (KPC mice) Model -
¡MX-110 + PD-1 Combination
4
▲▲▲▲▲
A
A
A
T
8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100
Days from Enrollment
A
Perelman Winograd et al; Cancer Immunol Res. 2015 Apr;3(4):399-411.
UTY of PANTA
KPC Mice Survival (90 Days)
AAAAA
A ▲ A
AAAAA
A A A
IMX-110 + PD-1 (n=3)
Isotype Alone (n=6-8)
CD40/G/nP (n=6-8)
0
4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100
Days from Enrollment
Source/Adapted from: Immix Biopharma, Inc. Winograd et al. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in
Pancreatic Carcinoma. Cancer Immunol Res..2015 Apr;3(4):399-411. doi: 10.1158/2326-6066.CIR-14-0215. Epub 2015 Feb 12.
Immix Biopharma Dosing: IMX-110 dosed based on doxorubicin at 1.5 mg/kg, aPD-1 (RMP1-14; BioXcell) 100µg/dose
Winograd, et al Dosing: gemcitabine (Eli Lilly) 120 mg/kg, nab-paclitaxel (Sigma) 108 mg/kg, aCD40 (FGK45; BioXcell) 100μg/dose, aPD-1 (RMP1-14; BioXcell) 200µg/dose
PD-1 alone (n=6-8)
CD40/G/nP+ PD-1 (n=6-8)
Individual Mice - Luciferase
activity (tumor growth) activity
●●●
IMMİX
S BIOPHARMA
Mouse A 1663 (pdx1-Cre)
¡MX-110 + PD-1
Mouse B 1689 (p48-Cre)
Perelman
SCHOOL OF MEDICINE
¡MX-110 + PD-1
IMMIX ¡MX-110 (n=3)
All Mice
Tumor Frequency
100%
100%
47View entire presentation